<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Pharm Res</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Pharm Res</journal-id><journal-id journal-id-type="publisher-id">IJPR</journal-id><journal-title-group><journal-title>Iranian Journal of Pharmaceutical Research : IJPR</journal-title></journal-title-group><issn pub-type="ppub">1735-0328</issn><issn pub-type="epub">1726-6890</issn><publisher><publisher-name>Shaheed Beheshti University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6094432</article-id><article-id pub-id-type="publisher-id">ijpr-17-906</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Design, Synthesis and Evaluation of Substituted Aryl-2-Nitrovinyl Derivatives as Small Molecules Proteasome Inhibitors </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Faghih Akhlaghi</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="affa">a</xref></contrib><contrib contrib-type="author"><name><surname>Daeihamed</surname><given-names>Marjan</given-names></name><xref ref-type="aff" rid="affb">b</xref></contrib><contrib contrib-type="author"><name><surname>Ayatollahi</surname><given-names>Seyed Abdolmajid</given-names></name><xref ref-type="aff" rid="affc">c</xref><xref ref-type="aff" rid="affd">d</xref></contrib><contrib contrib-type="author"><name><surname>Kobarfard</surname><given-names>Farzad</given-names></name><xref ref-type="aff" rid="affa">a</xref><xref ref-type="aff" rid="affc">c</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ata</surname><given-names>Athar</given-names></name><xref ref-type="aff" rid="affd">d</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="affa">
<label>a</label>
<italic>Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Iran. </italic>
</aff><aff id="affb">
<label>b</label>
<italic>Department of Pharmaceutics, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran. </italic>
</aff><aff id="affc">
<label>c</label>
<italic>Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</italic>
</aff><aff id="affd">
<label>d</label>
<italic> Department of Chemistry, Richardson College of the Environmental Science Complex, The University of Winnipeg, Winnipeg, Canada.</italic>
</aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author: E-mail: farzadkf@yahoo.com; a.ata@uwinnipeg.ca</corresp></author-notes><pub-date pub-type="ppub"><season>Summer</season><year>2018</year></pub-date><volume>17</volume><issue>3</issue><fpage>906</fpage><lpage>916</lpage><history><date date-type="received"><month>8</month><year>2017</year></date><date date-type="accepted"><month>3</month><year>2018</year></date></history><permissions><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Based on the existing structure activity relationship for proteasome inhibitors, a number of substituted aryl-2-nitrovinyl derivatives have been synthesized as Michael acceptor and their cytotoxicity and proteasome inhibitory effects were evaluated on two cancer cell lines. </plain></SENT>
<SENT sid="2" pm="."><plain>Compound 2d exhibited IC50 values of 0.71 and 17.79 μM comparable to bortezomib against MCF-7 and PC-3, respectively. </plain></SENT>
<SENT sid="3" pm="."><plain>The results show that the electronic properties and steric hindrance can affect the interaction of these small molecules with their receptor at the active site of the enzyme while the presence of CH2OH group on α-carbon of Michael acceptor is favorable, and para substitution of OMe on phenyl ring of β-carbon can increase the inhibitory potencies. </plain></SENT>
<SENT sid="4" pm="."><plain>Molecular docking studies confirm our experimental findings about mode of binding of our compounds with 20S proteasome. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><title>Key Words</title><kwd>Proteasome inhibitor</kwd><kwd>Small molecule</kwd><kwd>α</kwd><kwd>β-unsaturated nitro</kwd><kwd>Michael acceptor</kwd><kwd>Aryl-2-nitrovinyl</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="5" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="6" pm="."><plain>The ubiquitin-proteasome system (UPS) is the major intracellular protein degradation pathway in eukaryotic cells. </plain></SENT>
<SENT sid="7" pm="."><plain>This regulated pathway is responsible for more than 80% of intracellular protein degradation and controls most of the key cellular functions (1, 2). </plain></SENT>
<SENT sid="8" pm="."><plain>Studies have shown the essential role of UPS in most vital cellular functions, such as cell cycling, signal transduction, immune responses, and apoptosis (3). </plain></SENT>
<SENT sid="9" pm="."><plain>Protein degradation in the UPS consists of two major steps: the modification of a substrate by addition of poly ubiquitin chain; and subsequent degradation of ubiquitinated protein by 26S proteasome which is a multicatalytic proteinase complex (4, 5). </plain></SENT>
<SENT sid="10" pm="."><plain>Because of the functional role of this enzyme in cell survival, it has emerged as a promising therapeutic target and proteasome inhibitors have been investigated extensively as potential antitumor, antiviral, anti-inflammatory, and immunosuppressive agents. </plain></SENT>
<SENT sid="11" pm="."><plain>Furthermore, studies have indicated that tumor cells are more sensitive to proteasome inhibitors than normal cells, and therefore, the proteasome is regarded as one of the most promising antitumor drug targets (6, 7). </plain></SENT>
</text></p><p><text><SENT sid="12" pm="."><plain>The 26S proteasome is a large multi catalytic protein complex, consisting of a cylindrical 20S proteolytic core and two 19S regulatory particles. </plain></SENT>
<SENT sid="13" pm="."><plain>The 20S core which is responsible for protein degradation comprises of 2 pairs of 14 different subunits and the active sites of the 20S proteasome are located on the β1, β2, and β5 subunits, with caspase-like (C-L), trypsin-like (T-L), and chymotrypsin-like (ChT-L) activities, respectively (3). </plain></SENT>
<SENT sid="14" pm="."><plain>In all three β-subunits the cleavage of peptide bonds occurs through a mechanism in which the hydroxyl group of N-terminal catalytic threonine residue (Thr1) serves as the nucleophile (2). </plain></SENT>
</text></p><p><text><SENT sid="15" pm="."><plain>The high rate of protein production in cancer cells and the need for proteasome function in these cells for keeping up the cancer cell survival and proliferation, makes the proteasome pathway a validated target for cancer therapy. </plain></SENT>
<SENT sid="16" pm="."><plain>After the FDA approval of bortezomib, as a clinically effective reversible inhibitor of the β5 subunit, various proteasome inhibitors have been studied to combat the existing limitations. </plain></SENT>
<SENT sid="17" pm="."><plain>However, investigations for safer and less toxic alternatives with better pharmacokinetic properties are proceeding (8). </plain></SENT>
<SENT sid="18" pm="."><plain>Most proteasome inhibitors are composed of a short peptide backbone with an electrophilic trap to capture the hydroxyl group of the N-terminal threonine active site (9). </plain></SENT>
<SENT sid="19" pm="."><plain>However, these peptide-based drugs are susceptible to degradation and pose short in-vivo half-life. </plain></SENT>
<SENT sid="20" pm="."><plain>As peptide-based drugs suffer from some other limitations like chemical instability, immunogenicity and poor membrane permeability, efforts have been made to develop non-peptide synthetic proteasome inhibitors in the recent years (10). </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>The majority of proteasome inhibitors bear an electrophilic trap like epoxyketone, boronic acid, and aldehyde functional groups in their structures (11). </plain></SENT>
<SENT sid="22" pm="."><plain>In 1997 Bogyo et al. (12) introduced a new class of proteasome inhibitors with vinyl sulfone structure acting as a Michael acceptor pharmacophore. </plain></SENT>
<SENT sid="23" pm="."><plain>Furthermore, Overkleeft et al. (13) proposed various Michael acceptor containing peptide-based structures as proteasome inhibitors. </plain></SENT>
<SENT sid="24" pm="."><plain>On the other hand, studies of Baldisserotto et al. (14) showed that compounds bearing α,β-dehydro-phenylalanine are good substrates for Michael addition for catalytic threonine. </plain></SENT>
<SENT sid="25" pm="."><plain>In sight of these facts and aiming to find non-peptide small molecules, we have considered the synthesis and evaluation of proteasome inhibitory activity of small molecules bearing an α, β-unsaturated nitro functional group as a Michael acceptor in their structure. </plain></SENT>
<SENT sid="26" pm="."><plain>In this study, a series of substituted aryl-2-nitrovinyl derivatives were designed and synthesized. </plain></SENT>
<SENT sid="27" pm="."><plain>Docking studies were conducted for the synthesized compounds and the biological activities were also evaluated and compared to a known proteasome inhibitor, bortezomib. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec><title><text><SENT sid="28" pm="."><plain>Experimental </plain></SENT>
</text></title><p><text><SENT sid="29" pm="."><plain>General methods </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>All the chemicals and solvents were purchased from Merck (Darmstadt, Germany). </plain></SENT>
<SENT sid="31" pm="."><plain>The melting points of the compounds were measured on 9100 Electrothermal melting point apparatus. </plain></SENT>
<SENT sid="32" pm="."><plain>Elemental analyses were performed by a Costech ECS 4010 CHNS analyzer. </plain></SENT>
<SENT sid="33" pm="."><plain>The 1H-NMR spectra were recorded on a 400 MHz Bruker spectrometer. </plain></SENT>
<SENT sid="34" pm="."><plain>IR spectra were recorded on Perkin Elmer IR spectrophotometer as potassium bromide discs. </plain></SENT>
<SENT sid="35" pm="."><plain>GC–MS analysis were carried out by using a 7000 Agilent triple Quadrupole MS system coupled with a 7890A GC, equipped with a split/splitless injection port, an autosampler model Agilent 7693, and electronic ionization. </plain></SENT>
<SENT sid="36" pm="."><plain>A HP-5MS 5% Phenyl Methyl Silox, Agilent 19091s-433 capillary column was used (30 m × 0.25 mm I.D. and 0.25 μm film thickness). </plain></SENT>
<SENT sid="37" pm="."><plain>Helium gas with a purity of 99.99% and a flow rate of 1 mL/min was used as the carrier gas. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>General procedure for the synthesis of para-substituted nitrostyrene (1a-e) </plain></SENT>
</text></p><p><text><SENT sid="39" pm="."><plain>Nitromethane (0.1 moles) and the appropriate aldehyde (0.1 moles) were dissolved in 20 mL of methanol in a beaker that was kept cool by a mixture of ice and salt. </plain></SENT>
<SENT sid="40" pm="."><plain>A cold solution of sodium hydroxide (10 mL, 0.2 M) was added from an addition funnel to the stirring solution of nitromethane and benzaldehyde at a rate that the temperature was kept below 15 °C. </plain></SENT>
<SENT sid="41" pm="."><plain>A precipitate was formed and got thick during the addition of sodium hydroxide solution. </plain></SENT>
<SENT sid="42" pm="."><plain>After fifteen minutes remaining in the lab, about 60 mL of ice water was added to the mixture and the pasty mass was converted to a clear solution. </plain></SENT>
<SENT sid="43" pm="."><plain>The reaction mixture was added dropwise to a solution of HCl (20 mL of concentrated HCl diluted to 50 mL with water). </plain></SENT>
<SENT sid="44" pm="."><plain>A solid crystalline mass was formed and separated by decantation. </plain></SENT>
<SENT sid="45" pm="."><plain>The residue was filtered and washed with water and recrystallized from ethanol (15). </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>(2-nitrovinyl)benzene (1a): Yellow solid. </plain></SENT>
<SENT sid="47" pm="."><plain>Yield: 83%. mp 57-58 °C. </plain></SENT>
<SENT sid="48" pm="."><plain>IR (KBr): 1635, 1523, 1348, 973, 778. </plain></SENT>
<SENT sid="49" pm="."><plain>GC-MS (m/z): 149.1 [M]+. 1H-NMR (400 MHz, CDCl3): 7.43-7.56 (5H, m, CHPh), 7.59 (1H; d, J = 13.7 Hz; =CHα), 8.01 (1H; d, J = 13.7 Hz; =CHβ). </plain></SENT>
<SENT sid="50" pm="."><plain>Anal. </plain></SENT>
<SENT sid="51" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="52" pm="."><plain>For C8H7NO2 (149.15): C, 64.42; H, 4.73; N, 9.39; O, 21.45. </plain></SENT>
<SENT sid="53" pm="."><plain>Found: C, 64.37; H, 4.69; N, 9.41; O, 21.38. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>1-chloro-4-(2-nitrovinyl)benzene (1b): Crystalline (needle shape), light yellowish solid. </plain></SENT>
<SENT sid="55" pm="."><plain>Yield: 46%. mp 111-113 °C. </plain></SENT>
<SENT sid="56" pm="."><plain>IR (KBr): 1627, 1587, 1525, 1343, 979. </plain></SENT>
<SENT sid="57" pm="."><plain>GC-MS (m/z): 183.0 [M]+. 1H-NMR (400 MHz, CDCl3): 7.44 (2H; d, J = 8.6 Hz; CHAr-O-Cl), 7.49 (2H; d, J = 8.6 Hz; CHAr-m-Cl), 7.56 (1H; d, J = 13.7 Hz; =CHα), 7.96 (1H; d, J = 13.7 Hz; =CHβ). </plain></SENT>
<SENT sid="58" pm="."><plain>Anal. </plain></SENT>
<SENT sid="59" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="60" pm="."><plain>For C8H6ClNO2 (183.59): C, 52.34; H, 3.29; Cl, 19.31; N, 7.63; O, 17.43. </plain></SENT>
<SENT sid="61" pm="."><plain>Found: C, 52.32; H, 3.30; Cl, 19.30; N, 7.63; O, 17.41. </plain></SENT>
</text></p><p><text><SENT sid="62" pm="."><plain>1-methyl-4-(2-nitrovinyl)benzene (1c): Yellow solid. </plain></SENT>
<SENT sid="63" pm="."><plain>Yield: 57%. mp 105-106 °C; IR (KBr): 1628, 1514, 1345, 967, 815. </plain></SENT>
<SENT sid="64" pm="."><plain>GC-MS (m/z): 163.1 [M]+. 1H-NMR (400 MHz, CDCl3): 2.41 (3H, s, Me), 7.26 (2H; d, J = 8Hz; CHAr-o-Me), 7.45 (2H; d, J = 8Hz; CHAr-m-Me), 7.57 (1H; d, J = 13.6 Hz; =CHα ), 7.99 (1H; d, J = 13.6 Hz; =CHβ). </plain></SENT>
<SENT sid="65" pm="."><plain>Anal. </plain></SENT>
<SENT sid="66" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="67" pm="."><plain>For C9H9NO2 (163.17): C, 66.25; H, 5.56; N, 8.58; O, 19.61. </plain></SENT>
<SENT sid="68" pm="."><plain>Found: C, 66.22; H, 5.57; N, 8.56; O, 19.60. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>Scheme 1</label><caption><p><text><SENT sid="69" pm="."><plain>The synthetic pathway for preparation of para-substituted nitrostyrenes (1a-e) and 2-nitro-3-arylprop-2-en-1-ols (2a-d). </plain></SENT>
<SENT sid="70" pm="."><plain>Reagents and conditions: a) NaOH, temp. &lt; 15 °C; b) Imidazole, anthranilic acid, formaldehyde solution, r. t </plain></SENT>
</text></p></caption><graphic xlink:href="ijpr-17-906-g001"/></fig></SecTag><SecTag type="FIG"><fig id="F2" position="float"><label>Scheme 2</label><caption><p><text><SENT sid="71" pm="."><plain>The synthetic pathway for preparation of aryl-2-nitroallylbenzene (4a-e). </plain></SENT>
<SENT sid="72" pm="."><plain>Reagents and conditions: a) Silica gel, NaBH4, 2-propanol and chloroform; b) Dimethylamine hydrochloride, potassium fluoride, toluene. </plain></SENT>
</text></p></caption><graphic xlink:href="ijpr-17-906-g002"/></fig></SecTag><SecTag type="FIG"><fig id="F3" position="float"><label>Scheme 3</label><caption><p><text><SENT sid="73" pm="."><plain>The synthetic pathway for preparation of Aryl-4-methyl-2-nitropent-1-ene (6a-b). </plain></SENT>
<SENT sid="74" pm="."><plain>Reagents and conditions: a) Isopentyl iodide, sodium nitrite, DMF, 0 °C; b) n-BuNH2, methanol and acetic acid, 0 °C, under argon. </plain></SENT>
</text></p></caption><graphic xlink:href="ijpr-17-906-g003"/></fig></SecTag><SecTag type="FIG"><fig id="F4" position="float"><label>Figure 1</label><caption><p><text><SENT sid="75" pm="."><plain>Chemical structure of NIP-Leu3-Vinyl sulfone as a representative of vinyl sulfones </plain></SENT>
</text></p></caption><graphic xlink:href="ijpr-17-906-g004"/></fig></SecTag><SecTag type="FIG"><fig id="F5" position="float"><label>Figure 2</label><caption><p><text><SENT sid="76" pm="."><plain>Chemical structure of Lactacystin and its derivatives </plain></SENT>
</text></p></caption><graphic xlink:href="ijpr-17-906-g005"/></fig></SecTag><SecTag type="FIG"><fig id="F6" position="float"><label>Figure 3</label><caption><p><text><SENT sid="77" pm="."><plain>Binding of compound 4d in the active site of β5-subunit of 20S proteasome </plain></SENT>
</text></p></caption><graphic xlink:href="ijpr-17-906-g006"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="78" pm="."><plain>Cytotoxicity and proteasome ChT-L inhibitory activities of substituted aryl-2-nitrovinyl derivatives on MCF-7 and PC-3 cell lines. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain> </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="80" pm="."><plain>[a]Values represent the mean ± SD of three independent experiments, each based on four biological replicates. [b]Percent inhibition at 10 µM. [c] Percent inhibition at 25 µM. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="81" pm="."><plain>1-methoxy-4-(2-nitrovinyl) benzene (1d): Crystalline (needle shape) yellow solid. </plain></SENT>
<SENT sid="82" pm="."><plain>Yield: 96%. mp 84-86 °C; IR (KBr): 1624, 1509, 1419, 1324, 973. </plain></SENT>
<SENT sid="83" pm="."><plain>GC-MS (m/z): 179.1 [M]+. 1H-NMR (400 MHz, CDCl3): 3.87 (3H, s, OMe), 6.95 (2H; d, J = 8.8 Hz; CHAr-o-OMe), 7.49-7.54 (3H, m, CHAr-m-OMe and =CHα), 7.97 (1H; d, J = 13.6 Hz; =CHβ). </plain></SENT>
<SENT sid="84" pm="."><plain>Anal. </plain></SENT>
<SENT sid="85" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="86" pm="."><plain>For C9H9NO3 (179.17): C, 60.33; H, 5.06; N, 7.82; O, 26.79. </plain></SENT>
<SENT sid="87" pm="."><plain>Found: C, 60.31; H, 5.08; N, 7.80; O, 26.79. </plain></SENT>
</text></p><p><text><SENT sid="88" pm="."><plain>N, N-dimethyl-4-(2-nitrovinyl)benzenamine (1e): Red solid. </plain></SENT>
<SENT sid="89" pm="."><plain>Yield: 30%. mp 182-184 °C; IR (KBr): 1668, 1547, 1493, 1339, 981. </plain></SENT>
<SENT sid="90" pm="."><plain>GC-MS (m/z): 192.1 [M]+. 1H-NMR (400 MHz, CDCl3): 3.08 (6H, s, CHN(Me)2), 6.9 (2H; d, J = 8.9 Hz; CHAr-o-N(Me)2), 7.43 (2H; d, J = 8.9 Hz; CHAr-m-N(Me)2), 7.50 (1H, d, J = 13.4 Hz; =CHα), 7.97 (1H, d, J = 13.4 Hz; =CHβ). </plain></SENT>
<SENT sid="91" pm="."><plain>Anal. </plain></SENT>
<SENT sid="92" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="93" pm="."><plain>For C10H12N2O2 (192.21): C, 62.49; H, 6.29; N, 14.57; O, 16.65. </plain></SENT>
<SENT sid="94" pm="."><plain>Found: C, 62.48; H, 6.29; N, 14.55; O, 16.66. </plain></SENT>
</text></p><p><text><SENT sid="95" pm="."><plain>General procedure for the synthesis of 2-nitro-3-arylprop-2-en-1-ol (2a-d) </plain></SENT>
</text></p><p><text><SENT sid="96" pm="."><plain>To a stirred solution of substituted nitrostyrene (10 mmol) in THF (25 mL) at room temperature, imidazole (1 equivalent) and anthranilic acid (10 mol%) were added. </plain></SENT>
<SENT sid="97" pm="."><plain>Aqueous solution of formaldehyde (37%, 25 mL) was then added and the mixture was stirred at room temperature overnight. </plain></SENT>
<SENT sid="98" pm="."><plain>After completion of the reaction (monitored by TLC), the mixture was acidified with 5 M HCl (20 mL) and the aqueous layer was extracted with EtOAc (3 × 25 mL). </plain></SENT>
<SENT sid="99" pm="."><plain>The organic layers were washed with brine (50 mL), dried with anhydrous Na2SO4, and concentrated .The residue was purified by column chromatography (silica gel, EtOAc–hexanes, 0–30%, gradient elution) to obtain pure product (16). </plain></SENT>
</text></p><p><text><SENT sid="100" pm="."><plain>2-Nitro-3-phenylprop-2-en-1-ol (2a): Yellow oil. </plain></SENT>
<SENT sid="101" pm="."><plain>Yield: 53%. </plain></SENT>
<SENT sid="102" pm="."><plain>IR (neat): 3437, 1658, 1531, 1238, 1027, 783. </plain></SENT>
<SENT sid="103" pm="."><plain>GC-MS (m/z): 179.1 [M]+. 1H-NMR (400 MHz, CDCl3): 2.67 (1H, s, br), 4.72 (2H, s, CH2), 7.48-7.58 (5H, m, CHPh), 8.22 (1H, s, =CH). </plain></SENT>
<SENT sid="104" pm="."><plain>Anal. </plain></SENT>
<SENT sid="105" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="106" pm="."><plain>For C9H9NO3 (179.17): C, 60.33; H, 5.06; N, 7.82; O, 26.79. </plain></SENT>
<SENT sid="107" pm="."><plain>Found: C, 60.35; H, 5.06; N, 7.79; O, 26.80. </plain></SENT>
</text></p><p><text><SENT sid="108" pm="."><plain>2-Nitro-3-(4-chlorophenyl)prop-2-en-1-ol (2b): Pale yellow oil. </plain></SENT>
<SENT sid="109" pm="."><plain>Yield: 32%. </plain></SENT>
<SENT sid="110" pm="."><plain>IR (neat): 3441, 1636, 1506, 1453, 1091, 841. </plain></SENT>
<SENT sid="111" pm="."><plain>GC-MS (m/z): 213.0 [M]+. 1H-NMR (400 MHz, CDCl3): 2.66 (1H, s, br), 4.67 (2H, s, CH2), 7.46 (2H; d, J = 8 Hz; CHAr-o-Cl), 7.52 (2H; d, J = 8 Hz; CHAr-m-Cl), 8.16 (1H, s, =CH). </plain></SENT>
<SENT sid="112" pm="."><plain>Anal. </plain></SENT>
<SENT sid="113" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="114" pm="."><plain>For C9H8ClNO3 (213.62): C, 50.60; H, 3.77; Cl, 16.60; N, 6.56; O, 22.47. </plain></SENT>
<SENT sid="115" pm="."><plain>Found: C, 50.59; H, 3.78; Cl, 16.62; N, 6.54; O, 22.46. </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>2-Nitro-3-(4-tolyl)prop-2-en-1-ol (2c): Yellow solid. </plain></SENT>
<SENT sid="117" pm="."><plain>Yield: 38%. mp 52–54 °C. </plain></SENT>
<SENT sid="118" pm="."><plain>IR (KBr): 3444, 1660, 1539, 1342, 1030, 833. </plain></SENT>
<SENT sid="119" pm="."><plain>GC-MS (m/z): 193.1 [M]+. 1H-NMR (400 MHz, CDCl3): 2.42 (3H, s, Me), 2.67 (1H, s, br), 4.71 (2H; s, CH2), 7.29 (2H; d, J = 8 Hz; CHAr-o-Me), 7.47 (2H; d, J = 8 Hz; CHAr-m-Me), 8.19 (1H, s, =CH). </plain></SENT>
<SENT sid="120" pm="."><plain>Anal. </plain></SENT>
<SENT sid="121" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="122" pm="."><plain>For C10H11NO3 (193.2): C, 62.17; H, 5.74; N, 7.25; O, 24.84. </plain></SENT>
<SENT sid="123" pm="."><plain>Found: C, 62.15; H, 5.74; N, 7.23; O, 24.85. </plain></SENT>
</text></p><p><text><SENT sid="124" pm="."><plain>2-Nitro-3-(4-methoxyphenyl)prop-2-en-1-ol (2d): Yellow solid. </plain></SENT>
<SENT sid="125" pm="."><plain>Yield: 54%. mp 71–73 °C. </plain></SENT>
<SENT sid="126" pm="."><plain>IR (KBr): 3424, 1636, 1512, 1382, 1024, 831. </plain></SENT>
<SENT sid="127" pm="."><plain>GC-MS (m/z): 209.1 [M]+. 1H-NMR (400 MHz, CDCl3): 2.62 (1H, s, br), 3.48 (3H, s, OMe), 4.73 (2H, s, CH2), 6.99 (2H; d, J = 8 Hz; CHAr-o-OMe), 7.50 (2H; d, J = 8 Hz; CHAr-m-OMe), 8.19 (1H, s, =CH). </plain></SENT>
<SENT sid="128" pm="."><plain>Anal. </plain></SENT>
<SENT sid="129" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="130" pm="."><plain>For C10H11NO4 (209.2): C, 57.41; H, 5.30; N, 6.70; O, 30.59. </plain></SENT>
<SENT sid="131" pm="."><plain>Found: C, 57.43; H, 5.31; N, 6.69; O, 30.60. </plain></SENT>
</text></p><p><text><SENT sid="132" pm="."><plain>Synthesis of (2-nitroethyl)benzene (3) </plain></SENT>
</text></p><p><text><SENT sid="133" pm="."><plain>To the stirred mixture of nitrostyrene (1a, 10 mmol), silica gel (20 g, column chromatography grade), 2-propanol (30 mL), and chloroform (160 mL) was added NaBH4 (40 mmol) in small portions over a period of 15 min at room temperature. </plain></SENT>
<SENT sid="134" pm="."><plain>The mixture was stirred for additional 15 min until the yellow color was completely disappeared. </plain></SENT>
<SENT sid="135" pm="."><plain>Excess NaBH4 was decomposed by addition of diluted HCl (0.1 N) and the mixture was filtered and washed with CH2C12. </plain></SENT>
<SENT sid="136" pm="."><plain>The combined filtrate was washed with brine, dried (Na2SO4) and then evaporated to give (2-nitroethyl)benzene as a clear oil (17). </plain></SENT>
</text></p><p><text><SENT sid="137" pm="."><plain>IR (neat): 3063, 3031, 1608, 1555, 1380, 752. 1H-NMR (400 MHz, CDCl3): 5.44 (2H, s, CH2), 7.45-7.50 (5H, m, CHPh). </plain></SENT>
<SENT sid="138" pm="."><plain>Anal. </plain></SENT>
<SENT sid="139" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="140" pm="."><plain>For C8H9NO2 (151.16): C, 63.56; H, 6.00; N, 9.27; O, 21.17. </plain></SENT>
<SENT sid="141" pm="."><plain>Found: C, 63.55; H, 6.02; N, 9.26; O, 21.14. </plain></SENT>
</text></p><p><text><SENT sid="142" pm="."><plain>General procedure for the synthesis of aryl-2-nitroallylbenzene (4a-4e) </plain></SENT>
</text></p><p><text><SENT sid="143" pm="."><plain>A mixture of (2-nitroethyl)benzene (15 mmol), dimethylamine hydrochloride (30 mmol), potassium fluoride (2.25 mmol) and appropriate aldehyde (15 mmol) in toluene (20 mL) was refluxed with a Dean–Stark trap for 24 h. </plain></SENT>
<SENT sid="144" pm="."><plain>The reaction mixture was then diluted with toluene (100 mL) and washed with 10% HCl solution (3 × 30 mL). </plain></SENT>
<SENT sid="145" pm="."><plain>The organic phase was dried over anhydrous Na2SO4 and solvent evaporated in-vacuo. </plain></SENT>
<SENT sid="146" pm="."><plain>The product was purified by recrystallization in a mixture of EtOAc/hexane or column chromatography over silica gel (EtOAc/hexane, 7/3) (18). </plain></SENT>
</text></p><p><text><SENT sid="147" pm="."><plain>3-(phenyl)-2-nitroallylbenzene (4a): Yellow oil. </plain></SENT>
<SENT sid="148" pm="."><plain>Yield: 67%. </plain></SENT>
<SENT sid="149" pm="."><plain>IR (neat): 1649, 1533, 1392, 1331, 779. </plain></SENT>
<SENT sid="150" pm="."><plain>GC-MS (m/z): 239.1 [M]+. 1H-NMR (400 MHz, CDCl3): 4.27 (2H, s, CH2), 7.21-7.27 (5H, m, CHbenzyl ring), 7.42-7.47 (5H, m, CHPh), 8.31 (1H, s, =CH). </plain></SENT>
<SENT sid="151" pm="."><plain>Anal. </plain></SENT>
<SENT sid="152" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="153" pm="."><plain>For C15H13NO2 (239.27): C, 75.30; H, 5.48; N, 5.85; O, 13.37. </plain></SENT>
<SENT sid="154" pm="."><plain>Found: C, 75.28; H, 5.49; N, 5.83; O, 13.35. </plain></SENT>
</text></p><p><text><SENT sid="155" pm="."><plain>3-(4-chlorophenyl)-2-nitroallylbenzene (4b): Light brown solid. </plain></SENT>
<SENT sid="156" pm="."><plain>Yield: 78%. mp 98–100 °C. </plain></SENT>
<SENT sid="157" pm="."><plain>IR (KBr): 1651, 1520, 1325, 1021, 877. </plain></SENT>
<SENT sid="158" pm="."><plain>GC-MS (m/z): 273.1 [M]+. 1H-NMR (400 MHz, CDCl3): 4.22 (2H, s, CH2), 7.14 (2H; d, J = 8.4 Hz; CHAr-o-Cl), 7.29 (2H; d, J = 8.4 Hz; CHAr-m-Cl), 7.42-7.44 (5H, m, CHPh), 8.31 (1H, s, =CH). </plain></SENT>
<SENT sid="159" pm="."><plain>Anal. </plain></SENT>
<SENT sid="160" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="161" pm="."><plain>For C15H12ClNO2 (273.71): C, 65.82; H, 4.42; Cl, 12.95; N, 5.12; O, 11.69. </plain></SENT>
<SENT sid="162" pm="."><plain>Found: C, 65.80; H, 4.40; Cl, 12.94; N, 5.14; O, 11.70. </plain></SENT>
</text></p><p><text><SENT sid="163" pm="."><plain>3-(4-methylphenyl)-2-nitroallylbenzene (4c): Yellow-green solid. </plain></SENT>
<SENT sid="164" pm="."><plain>Yield: 73%. mp 105–107 °C. </plain></SENT>
<SENT sid="165" pm="."><plain>IR (KBr): 1665, 1520, 1393, 1329, 782. </plain></SENT>
<SENT sid="166" pm="."><plain>GC-MS (m/z): 253.1 [M]+. 1H-NMR (400 MHz, CDCl3): 2.32 (3H, s, Me), 4.22 (2H, s, CH2), 7.09-7.14 (4H, m, CHAr-o-Me and CHAr-m-Me), 7.40-7.46 (5H, m, CHPh), 8.28 (1H, s, =CH). </plain></SENT>
<SENT sid="167" pm="."><plain>Anal. </plain></SENT>
<SENT sid="168" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="169" pm="."><plain>For C16H15NO2 (253.3): C, 75.87; H, 5.97; N, 5.53; O, 12.63. </plain></SENT>
<SENT sid="170" pm="."><plain>Found: C, 75.88; H, 5.96; N, 5.53; O, 12.61. </plain></SENT>
</text></p><p><text><SENT sid="171" pm="."><plain>3-(4-methoxyphenyl)-2-nitroallylbenzene (4d): Yellow solid. </plain></SENT>
<SENT sid="172" pm="."><plain>Yield: 57%. mp 53–56 °C. </plain></SENT>
<SENT sid="173" pm="."><plain>IR (KBr): 1661, 1523, 1342, 1303, 878. </plain></SENT>
<SENT sid="174" pm="."><plain>GC-MS (m/z): 269.1 [M]+. 1H-NMR (400 MHz, CDCl3): 3.85 (3H, s, OMe), 4.31 (2H, s, CH2), 6.95 (2H; d, J = 8 Hz; CHAr-o-OMe), 7.20-7.39 (5H, m, CHPh), 7.45 (2H; d, J = 8 Hz, CHAr-m-OMe), 8.35 (1H, s, =CH). </plain></SENT>
<SENT sid="175" pm="."><plain>Anal. </plain></SENT>
<SENT sid="176" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="177" pm="."><plain>For C16H15NO3 (269.3): C, 71.36; H, 5.61; N, 5.20; O, 17.82. </plain></SENT>
<SENT sid="178" pm="."><plain>Found: C, 71.35; H, 5.62; N, 5.23; O, 17.80. </plain></SENT>
</text></p><p><text><SENT sid="179" pm="."><plain>N, N-dimethyl-4-(2-nitro-3-phenylprop-1-enyl)benzenamine (4e): Dark red solid. </plain></SENT>
<SENT sid="180" pm="."><plain>Yield: 76%. mp 110–113 °C. </plain></SENT>
<SENT sid="181" pm="."><plain>IR (KBr): 1599, 1530, 1386, 1252, 875. </plain></SENT>
<SENT sid="182" pm="."><plain>GC-MS (m/z): 282.1 [M]+. 1H-NMR (400 MHz, CDCl3): 3.02 (6H, s, N(Me)2), 4.34 (2H, s, CH2), 6.65 (2H; d, J = 9 Hz; CHAr-o-N(Me)2), 7.22-7.34 (5H, m, CHPh), 7.40 (2H; d, J = 9 Hz, CHAr-m- N(Me)2), 8.35 (1H, s, =CH). </plain></SENT>
<SENT sid="183" pm="."><plain>Anal. </plain></SENT>
<SENT sid="184" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="185" pm="."><plain>For C17H18N2O2 (282.34): C, 72.32; H, 6.43; N, 9.92; O, 11.33. </plain></SENT>
<SENT sid="186" pm="."><plain>Found: C, 72.30; H, 6.44; N, 9.94; O, 11.32. </plain></SENT>
</text></p><p><text><SENT sid="187" pm="."><plain>Synthesis of 3-methyl-1-nitrobutane (5) </plain></SENT>
</text></p><p><text><SENT sid="188" pm="."><plain>Isopentyl iodide (50.0 mmol) dissolved in DMF (40 mL) was added dropwise to a stirred solution of DMF (150 mL) and sodium nitrite (100.0 mmol) at 0 °C. </plain></SENT>
<SENT sid="189" pm="."><plain>The mixture was stirred overnight at room temperature. </plain></SENT>
<SENT sid="190" pm="."><plain>Water (500 mL) was then added to the mixture and it was extracted with petroleum ether (4 × 70 mL). </plain></SENT>
<SENT sid="191" pm="."><plain>The combined organic phase was washed with water (2 × 50 mL) and dried with Na2SO4. </plain></SENT>
<SENT sid="192" pm="."><plain>The solvent was evaporated under reduced pressure to give 3-methyl-1-nitrobutane as colorless oil. </plain></SENT>
</text></p><p><text><SENT sid="193" pm="."><plain>IR (neat): 2962, 2870, 1785, 1555, 1473, 1275, 1135. 1H-NMR (400 MHz, CDCl3): 0.89 (6H; d, J = 6.6 Hz; -CH3-isopropyl), 1.58-1.66 (1H, m, -CH-isopropyl), 1.85 (2H; q, J = 7.3 Hz; -CHβ), 4.34 (2H; t, J = 7.3 Hz, CH2). </plain></SENT>
<SENT sid="194" pm="."><plain>Anal. </plain></SENT>
<SENT sid="195" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="196" pm="."><plain>For C5H11NO2 (117.15): C, 51.26; H, 9.46; N, 11.96; O, 27.32. </plain></SENT>
<SENT sid="197" pm="."><plain>Found: C, 51.27; H, 9.46; N, 11.95; O, 27.30. </plain></SENT>
</text></p><p><text><SENT sid="198" pm="."><plain>General procedure for the synthesis of Aryl-4-methyl-2-nitropent-1-ene (6a-b) </plain></SENT>
</text></p><p><text><SENT sid="199" pm="."><plain>To a stirred solution of 3-methyl-1-nitrobutane (28 mmol) and appropriate aldehyde (28 mmol) in MeOH (20 mL), AcOH (1.08 mL, 18.8 mmol) and n-BuNH2 (1.86 mL, 18.8 mmol) were added at 0 °C under argon. </plain></SENT>
<SENT sid="200" pm="."><plain>After being stirred for 36 h at room temperature, the reaction mixture was poured into water and then extracted with EtOAc. </plain></SENT>
<SENT sid="201" pm="."><plain>The organic layer was washed with water and brine, dried over Na2SO4 and concentrated. </plain></SENT>
<SENT sid="202" pm="."><plain>The resultant residue was purified by column chromatography on silica gel (EtOAc/hexane, 1/20) (19). </plain></SENT>
</text></p><p><text><SENT sid="203" pm="."><plain>1-methyl-4-(4-methyl-2-nitropent-1-enyl)benzene (6a): Colorless oil. </plain></SENT>
<SENT sid="204" pm="."><plain>Yield: 40%. </plain></SENT>
<SENT sid="205" pm="."><plain>IR (neat): 1640, 1524, 1384, 1188, 770. </plain></SENT>
<SENT sid="206" pm="."><plain>GC-MS (m/z): 219.1 [M]+. 1H-NMR (400 MHz, CDCl3): 0.96 (6H; d, J = 6.8 Hz; -(CH3)2-isopropyl), 2.1 (1H; n, J = 6.8 Hz; -CH-isopropyl), 2.40 (3H, s, Me), 2.83 (2H; d, J = 7.2 Hz; CH2), 7.25 (2H; d, J = 8 Hz; CHAr-o-Me), 7.36 (2H; d, J = 8 Hz; CHAr-m-Me), 8.04 (1H, s, =CH). </plain></SENT>
<SENT sid="207" pm="."><plain>Anal. </plain></SENT>
<SENT sid="208" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="209" pm="."><plain>For C13H17NO2 (219.28): C, 71.21; H, 7.81; N, 6.39; O, 14.59. </plain></SENT>
<SENT sid="210" pm="."><plain>Found: C, 71.19; H, 7.80; N, 6.39; O, 14.60. </plain></SENT>
</text></p><p><text><SENT sid="211" pm="."><plain>1-methoxy-4-(4-methyl-2-nitropent-1-enyl)benzene (6b): Yellow oil. </plain></SENT>
<SENT sid="212" pm="."><plain>Yield: 44%. </plain></SENT>
<SENT sid="213" pm="."><plain>IR (neat): 1599, 1506, 1302, 1025, 832. </plain></SENT>
<SENT sid="214" pm="."><plain>GC-MS (m/z): 235.1 [M]+. 1H-NMR (400 MHz, CDCl3): 0.95 (6H; d, J = 6.8 Hz; -(CH3)2-isopropyl), 2.0 (1H; n, J = 6.8 Hz; -CH-isopropyl), 2.42 (2H; d, J = 7.2 Hz; CH2), 3.86 (3H, s, OMe), 6.97 (2H; d, J = 8 Hz; CHAr-o-OMe), 7.42 (2H; d, J = 8 Hz; CHAr-m-OMe), 8.05 (1H, s, =CH). </plain></SENT>
<SENT sid="215" pm="."><plain>Anal. </plain></SENT>
<SENT sid="216" pm="."><plain>Calcd. </plain></SENT>
<SENT sid="217" pm="."><plain>For C13H17NO3 (235.28): C, 66.36; H, 7.28; N, 5.95; O, 20.40. </plain></SENT>
<SENT sid="218" pm="."><plain>Found: C, 66.35; H, 7.29; N, 5.96; O, 20.39. </plain></SENT>
</text></p><p><text><SENT sid="219" pm="."><plain>Cell viability assays </plain></SENT>
</text></p><p><text><SENT sid="220" pm="."><plain>Human breast cancer (MCF-7), and human prostate cancer (PC-3) cells were cultured in their respective media supplemented with 10% fetal bovine serum (FBS). </plain></SENT>
<SENT sid="221" pm="."><plain>The cells were cultured at 1 × 104 cells per well, in a 96-well plate and incubated for 24-48 h to obtain cell attachments. </plain></SENT>
<SENT sid="222" pm="."><plain>Afterwards, the cells were treated with different concentrations of test compounds for 48 h and then incubated with 20 µL of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) solution for 4 h. </plain></SENT>
<SENT sid="223" pm="."><plain>After aspiration of the MTT solution, 100 µL of DMSO was added to each well to dissolve formazan crystals. </plain></SENT>
<SENT sid="224" pm="."><plain>The absorbance of each well was measured at the wavelength of 550 nm using an enzyme-linked immunosorbent assay reader. </plain></SENT>
<SENT sid="225" pm="."><plain>IC50 values were calculated from the curves generated by plotting the percentage of the viable cells versus the test concentration on a logarithmic scale using SigmaPlot 10.0 software. </plain></SENT>
</text></p><p><text><SENT sid="226" pm="."><plain>Cell-based proteasome inhibition assay  </plain></SENT>
</text></p><p><text><SENT sid="227" pm="."><plain>The effect of the derivatives on the 20S proteasome activity was determined using the 20S proteasome activity assay kit from Sigma (USA). </plain></SENT>
<SENT sid="228" pm="."><plain>This assay measures the ChT-L protease activity in cultured cells and is based on the detection of the fluorophore R110 after cleavage from the labeled substrate LLVY-R110. </plain></SENT>
<SENT sid="229" pm="."><plain>MCF-7 and PC-3 cells were pretreated with different concentrations of corresponding compounds and proteasome activities were determined according to the manufacturer′s protocol. </plain></SENT>
<SENT sid="230" pm="."><plain>Proteasome activity generates strongly green fluorescent R110, which was monitored at an excitation wavelength of 480 nm and emission of 590 nm on a microplate fluorescence reader. </plain></SENT>
<SENT sid="231" pm="."><plain>All data were calculated by subtracting the blank control. </plain></SENT>
<SENT sid="232" pm="."><plain>The data are presented as percent inhibition at a specific concentration (10 µM for MCF-7 and 25 µM for PC-3), and IC50 values obtained from dose–response curves utilizing curve-fitting software package SigmaPlot 10.0 software. </plain></SENT>
</text></p><p><text><SENT sid="233" pm="."><plain>Docking studies </plain></SENT>
</text></p><p><text><SENT sid="234" pm="."><plain>The crystal structure of 20S proteasome (PDB code: 4INR) was obtained from the RCSB Protein Data Bank. </plain></SENT>
<SENT sid="235" pm="."><plain>The molecular docking study was performed using AutoDock Vina v.1.1.2. </plain></SENT>
<SENT sid="236" pm="."><plain>Protein was prepared for docking by removing co-crystallized ligand and all water molecules from crystal protein. </plain></SENT>
<SENT sid="237" pm="."><plain>Polar hydrogens were added and nonpolar hydrogens were merged, finally Kallman unitedatom charge and atom type parameter were added to 4INR. </plain></SENT>
<SENT sid="238" pm="."><plain>Grid box dimensions (20 × 20 × 20) were set surrounding active site (20). </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec><title><text><SENT sid="239" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><p><text><SENT sid="240" pm="."><plain>Chemistry </plain></SENT>
</text></p><p><text><SENT sid="241" pm="."><plain>The routes of synthesis for substituted aryl-2-nitrovinyl derivatives are outlined in Schemes 1–3. </plain></SENT>
<SENT sid="242" pm="."><plain>The para-substituted nitrostyrenes (1a-e) were prepared by the reaction of nitromethane with the appropriate aldehyde. </plain></SENT>
<SENT sid="243" pm="."><plain>The obtained substituted nitrostyrenes (1a-d) were then converted to 2-nitro-3-arylprop-2-en-1-ols (2a-d) in the presence of imidazole, anthranilic acid, and formaldehyde solution at room temperature according to the synthetic route shown in Scheme 1. </plain></SENT>
</text></p><p><text><SENT sid="244" pm="."><plain>For synthesis of aryl-2-nitroallylbenzenes (4a-e), first (2-nitroethyl) benzene (3) was prepared by reduction of nitrostyrene (1a) in the presence of silica gel and NaBH4 in 2-propanol and chloroform. </plain></SENT>
<SENT sid="245" pm="."><plain>After that, compound 3 was reacted with appropriate aldehyde by adding dimethylamine hydrochloride and potassium fluoride in toluene. </plain></SENT>
</text></p><p><text><SENT sid="246" pm="."><plain>Aryl-4-methyl-2-nitropent-1-ene (6a-b) was synthesized by the reaction of 3-methyl-1-nitrobutane (5) with the appropriate aldehyde in methanol, in the presence of n-BuNH2 and acetic acid at 0 °C and under argon. </plain></SENT>
<SENT sid="247" pm="."><plain>3-methyl-1-nitrobutane (5) was prepared by the reaction of isopentyl iodide with sodium nitrite in DMF at 0 °C. </plain></SENT>
</text></p><p><text><SENT sid="248" pm="."><plain>Biological evaluation </plain></SENT>
</text></p><p><text><SENT sid="249" pm="."><plain>Proteasome inhibition have been proposed as a promising therapeutic target in medicinal chemistry and various reversible and irreversible proteasome inhibitors have been introduced in the literature (21). </plain></SENT>
<SENT sid="250" pm="."><plain>Most proteasome inhibitors are small peptides containing an electrophilic functional group at one end of their structures which form covalent bonds with the catalytic Oγ-threonine in the active site of 20S proteasome (10). </plain></SENT>
<SENT sid="251" pm="."><plain>Vinyl sulfones (Figure 1) were introduced as a pharmacophore in irreversible proteasome inhibitors by Bogyo et al. (12), and it is suggested that the hydroxyl group of the threonine residue in the active site of proteasome reacts with the double bond of vinyl sulfone moiety through a Michael addition mechanism. </plain></SENT>
</text></p><p><text><SENT sid="252" pm="."><plain>Conjugation of vinyl group with sulfone moiety makes these compounds good Michael acceptors and thus good proteasome inhibitors. </plain></SENT>
<SENT sid="253" pm="."><plain>In the present study we designed and synthesized a group of nitrovinyl compounds (α, β–unsaturated nitro compounds) which are chemically eligible Michael acceptors and they can then be considered as potential proteasome inhibitors. </plain></SENT>
<SENT sid="254" pm="."><plain>The reported structure activity relationship for different classes of proteasome inhibitors such as peptide-aldehydes, vinyl sulfones, peptide boronates (bortezomib) and epoxyketones indicate that the presence of an amino acid residue, such as leucine or phenylalanine, in the vicinity of the pharmacophore group will increase the efficiency of proteasome inhibitors. </plain></SENT>
<SENT sid="255" pm="."><plain>Therefore, we tried three residues next to the nitrovinyl moiety and investigated their impact on proteasome inhibitory activity. </plain></SENT>
<SENT sid="256" pm="."><plain>The three residues were isopropyl, benzyl and hydroxymethyl, and they were placed on the alpha carbon with respect to the nitro group to avoid any possible steric hindrance on beta carbon. </plain></SENT>
</text></p><p><text><SENT sid="257" pm="."><plain>The synthesized derivatives were tested for the antiproliferative and ChT-L proteasome inhibitory properties on two cancer cell lines including MCF-7 and PC-3 cells. </plain></SENT>
<SENT sid="258" pm="."><plain>A list of the designed compounds and their biological activity are summarized in Table 1. </plain></SENT>
<SENT sid="259" pm="."><plain>In order to investigate the nature of the interaction of these small molecules with the receptor, various functional groups with different lipophilicity, size and electronic properties were substituted at the R1 (Cl, CH3, OCH3, and N (CH3)2) and R2 (isopropyl, benzyl, or CH2OH) positions. </plain></SENT>
</text></p><p><text><SENT sid="260" pm="."><plain>As shown in Table 1, most of the substituted aryl-2-nitrovinyl derivatives, with the exception of compounds 1e and 4e showed promising inhibitory activities toward ChT-L in both cell lines, inhibiting &gt;40% of the proteasome activity at 10 and 25 µM concentrations for MCF-7 and PC-3, respectively. </plain></SENT>
<SENT sid="261" pm="."><plain>The 2-nitro-3-(4-methoxyphenyl)prop-2-en-1-ol (compound 2d) was the most potent proteasome inhibitor with IC50 values of 0.71 and 17.79 μM against MCF-7 and PC-3, respectively. </plain></SENT>
<SENT sid="262" pm="."><plain>These α,β–unsaturated nitro compounds also exhibited satisfactory cytotoxic effects against both MCF-7 (IC50 &lt; 25) and PC-3 (IC50 &lt; 80) cancer cell lines. </plain></SENT>
</text></p><p><text><SENT sid="263" pm="."><plain>Among the R2 substituted derivatives, compounds with a CH2OH group on the α-carbon position of the nitro group (2a, 2c, 2d), generally showed the highest ChT-L inhibitory effects. </plain></SENT>
<SENT sid="264" pm="."><plain>These compounds exhibited lower antiproliferative and proteasome inhibitory IC50 values on both cell lines. </plain></SENT>
<SENT sid="265" pm="."><plain>Introducing benzyl ring and isopropyl group at the R2 position resulted in lower activities (i.e. 4c and 6a versus 2c) and the following order was seen for proteasome inhibitory potencies in the R2 position: CH2OH &gt; H &gt; CH2-Ph &gt; CH (CH3)2; suggesting that parameters such as steric and electronic properties of the side chain on α-carbon position of the α,β-unsaturated nitro group may affect the activity of the compounds. </plain></SENT>
<SENT sid="266" pm="."><plain>Despite the fact that the best amino acid residue next to the pharmacophore group in boronates and vinyl sulfones seem to be isobutyl group, the presence of a hydroxymethyl group in the vicinity of pharmacophore moiety is also observed in the structures of Lactacystin (Figure 2) and its derivatives which are natural products with proteasome inhibitory activity. </plain></SENT>
</text></p><p><text><SENT sid="267" pm="."><plain>Maintaining the R2 position constant, various para-substituted (2-nitrovinyl)benzene derivatives were synthesized and evaluated for ChT-L inhibitory properties. </plain></SENT>
<SENT sid="268" pm="."><plain>The presence of OMe group at R1 position (1d, 2d, 4d, and 6b) significantly improved the antiproliferative and ChT-L proteasome inhibitory activities in each series. </plain></SENT>
<SENT sid="269" pm="."><plain>The replacement of OMe with other substituents including Me, Cl, and N (CH3)2 reduced proteasome inhibitory effects whereas no inhibitory effects (IC50 &gt; 50 μM) were observed for 1e and 4e in both cell lines, bearing N (CH3)2 group at R1 position. </plain></SENT>
<SENT sid="270" pm="."><plain>These results propose that the electronic properties of the substituent and steric hindrance at R1 position may have marked effects on ChT-L proteasome inhibitory properties. </plain></SENT>
</text></p><p><text><SENT sid="271" pm="."><plain>Docking studies </plain></SENT>
</text></p><p><text><SENT sid="272" pm="."><plain>Molecular docking studies were conducted to understand the interactions between the efficient derivatives and the active site of β5-subunit of the proteasome (Thr1). </plain></SENT>
<SENT sid="273" pm="."><plain>According to the results of docking studies (Figure 3), the distance between β-position of Michael acceptor and OH group of Thr1 in the active site of enzyme is about 3.1 Ǻ that can suggest the possibility of covalent interactions. </plain></SENT>
<SENT sid="274" pm="."><plain>The Gibbs free energy binding (ΔG), obtained from the result of molecular docking, showed that the more active derivatives have a satisfactory affinity to β5-subunit of proteasome with free binding energy of –6 kcal/mol. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions"><title><text><SENT sid="275" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="276" pm="."><plain>In the present study a series substituted aryl-2-nitrovinyl derivatives have been synthesized and their inhibitory activities were assessed against β5-subunit of the 20S proteasome in two cell lines. </plain></SENT>
<SENT sid="277" pm="."><plain>The tested derivatives inhibited proteasome activity and cell proliferation with good IC50 values on both cell lines. </plain></SENT>
<SENT sid="278" pm="."><plain>Among the tested compounds, compound 2d proved to be the most potent proteasome inhibitor with IC50 value of 0.71 and 17.79 μM against MCF-7 and PC-3, respectively. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgment</title><p><text4fund><text><SENT sid="279" pm="."><plain>This work was financially supported by Iran National Science Foundation (INSF). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="280" pm="."><plain>1Frankland-SearbySBhaumikSRThe 26S proteasome complex: An attractive target for cancer therapy Biochim. </plain></SENT>
<SENT sid="281" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="282" pm="."><plain>Acta 20121825647622037302 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="283" pm="."><plain>2KisselevAFvander Linden WAOverkleeftHSProteasome inhibitors: An expanding army attacking a unique target Chem. </plain></SENT>
<SENT sid="284" pm="."><plain>Biol2012199911522284358 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="285" pm="."><plain>3DelcrosJGFloc′hMBPrigentCArlot-BonnemainsYProteasome inhibitors as therapeutic agents: Current and future strategies Curr. </plain></SENT>
<SENT sid="286" pm="."><plain>Med. </plain></SENT>
<SENT sid="287" pm="."><plain>Chem20031047950312570694 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="288" pm="."><plain>4GallasteguiNGrollMThe 26S proteasome: Assembly and function of a destructive machine Trends Biochem. </plain></SENT>
<SENT sid="289" pm="."><plain>Sci2010356344220541423 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="290" pm="."><plain>5GrollMHuberRInhibitors of the eukaryotic 20S proteasome core particle: A structural approach Biochim. </plain></SENT>
<SENT sid="291" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="292" pm="."><plain>Acta 20041695334415571807 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="293" pm="."><plain>6KisselevAFGoldbergALProteasome inhibitors: From research tools to drug candidates Chem. </plain></SENT>
<SENT sid="294" pm="."><plain>Biol200187395811514224 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="295" pm="."><plain>7GeninEReboud-RavauxMVidalJProteasome inhibitors: Recent advances and new perspectives in medicinal chemistry Curr. </plain></SENT>
<SENT sid="296" pm="."><plain>Top. </plain></SENT>
<SENT sid="297" pm="."><plain>Med. </plain></SENT>
<SENT sid="298" pm="."><plain>Chem2010102325620166955 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="299" pm="."><plain>8BettigniesGCouxOProteasome inhibitors: Dozens of molecules and still counting Biochimie 20109215304520615448 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="300" pm="."><plain>9PevznerYMetcalfRKantorMSagaroDDanielKRecent advances in proteasome inhibitor discovery Expert Opin. </plain></SENT>
<SENT sid="301" pm="."><plain>Drug Discov201385376823547800 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="302" pm="."><plain>10BeckPDubiellaCGrollMCovalent and non-covalent reversible proteasome inhibition Biol. </plain></SENT>
<SENT sid="303" pm="."><plain>Chem201239311012023091276 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="304" pm="."><plain>11CrawfordLJWalkerBIrvineAEProteasome inhibitors in cancer therapy J. Cell Commun. </plain></SENT>
<SENT sid="306" pm="."><plain>Signal201151011021484190 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="307" pm="."><plain>12BogyoMMcMasterJSGaczynskaMTortorellaDGoldbergALPloeghHCovalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors Proc. </plain></SENT>
<SENT sid="308" pm="."><plain>Natl. </plain></SENT>
<SENT sid="309" pm="."><plain>Acad. </plain></SENT>
<SENT sid="310" pm="."><plain>Sci. </plain></SENT>
<SENT sid="311" pm="."><plain>USA 1997946629349192616 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="312" pm="."><plain>13LindenWAGeurinkPPOskamCvander Marel GAFloreaBIOverkleeftHSProteasome selectivity towards Michael acceptor containing oligopeptide-based inhibitors Org. </plain></SENT>
<SENT sid="313" pm="."><plain>Biomol. </plain></SENT>
<SENT sid="314" pm="."><plain>Chem2010818859320449494 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="315" pm="."><plain>14BaldisserottoAMarastoniMLazzariITrapellaCGavioliRTomatisRC-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors Eur. </plain></SENT>
<SENT sid="316" pm="."><plain>J. </plain></SENT>
<SENT sid="317" pm="."><plain>Med. </plain></SENT>
<SENT sid="318" pm="."><plain>Chem20084314031117996987 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="319" pm="."><plain>15WorrallDEOrganic Synthesis, Collective1941 New YorkWiley Publishers413 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="320" pm="."><plain>16BakthadossMSivakumarNDevarajAFirst synthesis of bromo and chloro derivatives of Baylis–Hillman adducts derived from nitroolefins: Application towards the synthesis of a Dendrimer core Sythesis 201146118 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="321" pm="."><plain>17SinhababuAKBoschardtRTSilica gel-assisted reduction of nitrostyrenes to 2-aryl-l-nitroalkanes with sodium borohydride Tetrahedron Lett. 19832422730 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="322" pm="."><plain>18KodukullaRTrivediGKJyotiDVHariHMSynthesis, chemical transformation and antimicrobial activity of a novel class of nitroolefins: 1,3-diaryl-2-nitroprop-l-enes Synth. </plain></SENT>
<SENT sid="323" pm="."><plain>Commun19942481932 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="324" pm="."><plain>19AsadaMIwahashiMObitsuTKinoshitaANakaiYOnodaTNagaseTTanakaMYamauraYTakizawaHYoshikawaKSatoKNaritaMOhuchidaSNakaiH and Toda M3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists Part 1: Discovery and exploration of the carboxyamide side chain Bioorg. </plain></SENT>
<SENT sid="325" pm="."><plain>Med. </plain></SENT>
<SENT sid="326" pm="."><plain>Chem201018809020004584 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="327" pm="."><plain>20TrottOOlsonAJAutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. </plain></SENT>
<SENT sid="329" pm="."><plain>Chem2010314556119499576 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="330" pm="."><plain>21EldridgeAGO′BrienTTherapeutic strategies within the ubiquitin proteasome system Cell Death Differ20101741319557013 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
